4588 — Oncolys Biopharma Balance Sheet
0.000.00%
Last trade - 00:00- ¥55bn
- ¥54bn
- ¥31m
Annual balance sheet for Oncolys Biopharma, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 3,455 | 1,711 | 1,533 | 2,411 | 3,675 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 377 | 318 | 102 | 148 | 420 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4,198 | 2,609 | 1,956 | 3,098 | 4,494 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0 | 0 | 0 | 0 | 0 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 4,292 | 2,651 | 2,041 | 3,199 | 4,556 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 430 | 322 | 379 | 252 | 471 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 698 | 492 | 567 | 447 | 556 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 3,594 | 2,159 | 1,474 | 2,752 | 4,000 |
| Total Liabilities & Shareholders' Equity | 4,292 | 2,651 | 2,041 | 3,199 | 4,556 |
| Total Common Shares Outstanding |